RxDoctor Payments Data

Emily Lowell

Physician Assistant · Omaha, NENPI 1841924982

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 573 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,536, more than ten times the $17 reported in 2023. Among physician assistant clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,875in general payments, 2019–2025

Across 573 payments — averaging $13.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$605
  • Lundbeck LLC$585
  • Teva Pharmaceuticals USA, Inc.$566
  • Neurocrine Biosciences, Inc.$512
  • UCB, Inc.$498
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$7,72698%
  • Education$1492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,875 in reported general payments places this provider in the 95th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$11,820
Medicare patients
23
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate12$15,593
Duloxetine Hcl38$469
Levetiracetam17$250
Gabapentin43$246
Lamotrigine18$207
Donepezil Hcl34$147
Topiramate16$126
Pregabalin14$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$382$15,59312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →